NCT01340651View on ClinicalTrials.gov

Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

41

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions

Myelofibrosis

Interventions

DRUG

Ruxolitinib

Ruxolitinib was supplied as SR and IR formulated tablets.

Trial Locations (3)

Unknown

Scottsdale

Winter Park

TX

Houston

Sponsors

Lead Sponsor

Incyte Corporation

All Listed Sponsors

lead

Incyte Corporation

INDUSTRY